MX2024010993A - Compuestos organicos. - Google Patents

Compuestos organicos.

Info

Publication number
MX2024010993A
MX2024010993A MX2024010993A MX2024010993A MX2024010993A MX 2024010993 A MX2024010993 A MX 2024010993A MX 2024010993 A MX2024010993 A MX 2024010993A MX 2024010993 A MX2024010993 A MX 2024010993A MX 2024010993 A MX2024010993 A MX 2024010993A
Authority
MX
Mexico
Prior art keywords
organic compounds
checkpoint inhibitor
inhibitor therapies
pde1
phosphodiesterase
Prior art date
Application number
MX2024010993A
Other languages
English (en)
Spanish (es)
Inventor
Robert E Davis
Maud Voisin
Stephen Goding
Gretchen L Snyder
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2024010993A publication Critical patent/MX2024010993A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024010993A 2022-03-11 2023-03-11 Compuestos organicos. MX2024010993A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263269209P 2022-03-11 2022-03-11
US202363479938P 2023-01-13 2023-01-13
PCT/US2023/064202 WO2023173131A2 (en) 2022-03-11 2023-03-11 Organic compounds

Publications (1)

Publication Number Publication Date
MX2024010993A true MX2024010993A (es) 2024-09-17

Family

ID=87936112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010993A MX2024010993A (es) 2022-03-11 2023-03-11 Compuestos organicos.

Country Status (8)

Country Link
US (1) US20250186446A1 (cg-RX-API-DMAC10.html)
EP (1) EP4489758A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025509446A (cg-RX-API-DMAC10.html)
KR (1) KR20240158980A (cg-RX-API-DMAC10.html)
AU (1) AU2023232171A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243686A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024010993A (cg-RX-API-DMAC10.html)
WO (1) WO2023173131A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2939676A1 (en) * 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
DK2970279T3 (da) * 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US11291666B2 (en) * 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
CA3047579A1 (en) * 2016-12-22 2018-06-28 Abbvie Inc. Compositions and methods of enhancing or augmenting type i ifn production
JP7493460B2 (ja) * 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020146384A1 (en) * 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) * 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment

Also Published As

Publication number Publication date
KR20240158980A (ko) 2024-11-05
AU2023232171A1 (en) 2024-08-22
JP2025509446A (ja) 2025-04-11
EP4489758A2 (en) 2025-01-15
CA3243686A1 (en) 2023-09-14
US20250186446A1 (en) 2025-06-12
WO2023173131A2 (en) 2023-09-14
WO2023173131A3 (en) 2023-10-19
EP4489758A4 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
WO2023173131A3 (en) Organic compounds
MX2024000054A (es) Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
MX2024000357A (es) Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
MX2021009563A (es) Combinacion farmaceutica que comprende tno155 y ribociclib.
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
PH12022552739A1 (en) Fused tricyclic kras inhibitors
PH12012501372B1 (en) Proteasome inhibitors and methods of using the same
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
WO2019067666A8 (en) Therapeutic methods relating to hsp90 inhibitors
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
MX2024011278A (es) Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
MX2019013862A (es) Terapia de combinacion.
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
MX2024000406A (es) Combinacion de inhibidores de puntos de control y un virus oncolitico para el tratamiento del cancer.
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
WO2020132560A3 (en) Compositions and methods for cancer therapy
MX2024000674A (es) Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
MX2025004037A (es) Inhibidor de perk hc-5404 en combinacion con un anticuerpo anti-pd-1 y/o un agente antiangiogentico para su uso en el tratamiento del cancer
MY162518A (en) Proteasome inhibitors and methods of using the same
MX2022011646A (es) Celulas t v delta1+ para el tratamiento de neoplasias mieloides.
WO2020055906A8 (en) Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)
MX2023014669A (es) Compuestos utiles en el tratamiento o prevencion de un trastorno mediado por prmt5.
WO2019173478A3 (en) Combination of depletes tregs and a checkpoint inhibitor
MX2021001764A (es) Terapia de combinacion.